Noriaki Yamamoto - Santen Pharmaceutical Insider

SNPHY -- USA Stock  

USD 16.45  0.06  0.34%

  Executive
We currently do not have informatin regarding Noriaki Yamamoto. This executive tanure with Santen Pharmaceutical Co Ltd is not currenlty determined.
        
81 6 6321 7000  http://www.santen.com

Management Efficiency

The company has return on total asset (ROA) of 6.82 % which means that it generated profit of $6.82 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 13.02 % meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 69 M in total debt with debt to equity ratio (D/E) of 2.6 implying the company greatly relies on financing operations through barroing. Santen Pharmaceutical Co Ltd has Current Ratio of 2.89 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Santen Pharmaceutical Co., Ltd., together with its subsidiaries, researches and develops, produces, and markets prescription ophthalmic pharmaceutical products for the protection and enhancement of eyesight and health primarily in Japan. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug Manufacturers - Major classification in USA and traded on OTC Market. It employs 3805 people.Santen Pharmaceutical Co Ltd (SNPHY) is traded on OTC Market in USA. It is located in Grand Front Osaka Tower A and employs 3,805 people.

Santen Pharmaceutical Co Leadership Team

Satoshi Suzuki, Executive Officer, Chief Director of Planning
Kanoko Ohishi, Independent Director
Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer
Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee
Hidetaka Mizutani, Manager of Finance & Accounting Group
Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR
Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director
Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel.
Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer
Akihiro Tsujimura, Executive Officer, Director of Asia Business
Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit
Frank Binder, Executive Officer, Chief Director of Supply Chain
Yutaro Shintaku, Independent Director
Akihiro Okumura, Independent Director
Yutaro Shinta, Independent Director
Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary
Shiro Hatagami, Manager of Finance & Accounting Group
Keizo Nakada, Executive Officer, Chief Director of Product Supply
Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee
Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary
Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics
Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Ye Liu, Executive Officer, General Manager of Subsidiary
Takayuki Katayama, Independent Director
Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary

Stock Performance Indicators

Current Sentiment - SNPHY

Santen Pharmaceutical Co Investor Sentiment
Macroaxis portfolio users are evenly split in their outlook on investing in Santen Pharmaceutical Co Ltd. What is your outlook on investing in Santen Pharmaceutical Co Ltd? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
MSFT   
Purchased over 20 shares of
a day ago
Traded for 106.27
F   
Purchased over 200 shares of
a day ago
Traded for 10.56
GM   
Purchased over 70 shares of
a day ago
Traded for 39.4
GOOG   
Purchased few shares of
a day ago
Traded for 1184.91
C   
Purchased over 40 shares of
a day ago
Traded for 69.22
Also please take a look at World Market Map. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">